“…Despite the positive results of several studies, FEIBA is not formally recognized by national societies as a therapeutic option for managing warfarin-associated coagulopathies [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. This finding may be driven by FEIBA lacking an FDA approval for this indication, the relatively small number of studies evaluating the use of FEIBA in the management of warfarin-associated coagulopathies compared to PCC, and the preconceived notion that FEIBA is more prothrombotic than PCC due to it containing activated factor VII.…”